|Back to main|
Aratana Therapeutics postpones $51 million IPO
6/18/2013 9:41:00 AM
By: Renaissance Capital
Aratana Therapeutics, which is developing medications for cats and dogs based on therapies for humans, postponed its IPO on Tuesday citing poor market conditions. The Kansas City, KS-based company was founded in 2010 and had expected to raise $51 million in its IPO by offering 4.3 million shares at a $11-$13 range. Stifel and Lazard Capital Markets were set to be the joint bookrunners on the deal.